---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-092735"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:47:30.666099+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines Q2 net loss $133M; advances RMC-6236 toward Phase 3 in PDAC

## Summary
- Q2 net loss $133.2M vs $98.3M YoY; revenue zero due to Sanofi collaboration termination.
- Cash $1.59B; projects funding into 2027; FY 2024 GAAP net loss guidance $560-600M.
- RMC-6236 in PDAC: median PFS 8.1 months (KRAS G12X); Phase 3 RASolute 302 planned for 2L this year.
- Board appoints Frank Clyburn, former Merck Keytruda leader; new senior hires in medical affairs.
- R&D expenses $134.9M vs $98.0M; G&A $21.7M vs $14.6M, driven by clinical and commercial prep.

## SEC filing metadata
- accession: 0000950170-24-092735
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000095017024092735/0000950170-24-092735-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000095017024092735/rvmd-20240805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-092735
- JSON: https://secwatch.observer/filing/0000950170-24-092735.json
- Plain text: https://secwatch.observer/filing/0000950170-24-092735.txt

## Key facts
- Executive change
  Frank K. Clyburn, Jr. was appointed as Director at Revolution Medicines, Inc..
  - Action: appointed
  - Role: Director
  source text: On August 5, 2024, the board of directors (the “Board”) of the Company increased the authorized size of the Board to ten directors and appointed Frank K. Clyburn, Jr. as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000095017024092735/0000950170-24-092735-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.